Letters to the Editor: Author reply to Letters to the Editor regarding ‘A challenge to the dopamine orthodoxy in schizophrenia?’

Abstract

Get full access to this article

View all access options for this article.

References

Dedic

Dworak

Zeni

, et al. (2021) Therapeutic potential of TAAR1 agonists in schizophrenia: Evidence from preclinical models and clinical studies. International Journal of Molecular Sciences 22: 13185.

Halff

Rutigliano

Garcia-Hidalgo

, et al. (2023) Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends in Neurosciences 46: 60–74.

Howes

Onwordi

(2023) The synaptic hypothesis of schizophrenia version III: A master mechanism. Molecular Psychiatry. Epub ahead of print 11 April. DOI: 10.1038/s41380-023-02043-w.

Kuhn

(1962) The Structure of Scientific Revolutions. Chicago, IL: University of Chicago Press.

Lugg

(2023) Regarding ‘A challenge to the dopamine orthodoxy in schizophrenia?’ Australian and New Zealand Journal of Psychiatry 57: 1395–1396.

Mulinari

(2012). Monoamine theories of depression: Historical impact on biomedical research. Journal of the History of the Neurosciences 21: 366–392.

Nair

Bastiampillai

(2023) Regarding ‘A challenge to the dopamine orthodoxy in schizophrenia’. Australian and New Zealand Journal of Psychiatry 57: 1394–1395.